Announcement

Collapse
No announcement yet.

New SPMS, PPMS treatment (but old drug) highly promising

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • New SPMS, PPMS treatment (but old drug) highly promising

    With a dearth of treatment options for secondary progressive and primary progressive multiple sclerosis, this new study certainly got my attention. - Dave


    Intrathecal methotrexate shows promising results on progressive Multiple Sclerosis patients

    The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology.

    This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.

    A retrospective, open-label, chart review analysis was conducted following patients with MS for up to eight treatments. Patients were considered for ITMTX treatment if they were unresponsive to or intolerant of FDA approved treatments.

    There was a one year follow-up after their eighth or last treatment.

    Patients underwent neurological assessments and Expanded Disability Status Scale (EDSS) evaluations.

    In 87 secondary progressive MS patients, EDSS scores were stable or improved in 89%, with significantly improved mean EDSS post-treatment compared to baseline. Of 34 primary progressive patients, EDSS scores were stable in 82%, with no significant progression in EDSS post-treatment compared to baseline.

    ITMTX may have a beneficial role in progressive forms of MS and is well tolerated with no serious adverse events.

    "We have opened an avenue of treatment for an otherwise untreatable form of MS," said Dr. Saud A. Sadiq, Director of the IMSMP/MSRCNY and the study's lead author. "This is exciting news because it's the first time a treatment has been shown to be effective in the late stages/progressive forms of MS."

    About Methotrexate

    Methotrexate (MTX), an antimetabolite, has been in clinical use since 1948 when it was found to produce temporary remission of acute childhood leukemia. Because of its indirect immunosuppressive effects, MTX is used in treating autoimmune conditions such as rheumatoid arthritis and psoriasis.

    About the IMSMP & MSRCNY

    The International Multiple Sclerosis Management Practice and the Multiple Sclerosis Research Center of New York is a leader in MS healthcare and research. As a center of excellence, it establishes an unparalleled level of care for individualized, compassionate attention to patients' needs and well-being. Patients receive in-depth assessments and management plans with on-site physical therapists, social workers and neuropsychologists for cognitive rehabilitation.
    Dave Bexfield
    ActiveMSers

  • #2
    imtra metho whatever ...

    Interesting Dave.
    Seriously progressing or where other treatments are no longer effective.
    Not sure I'm there yet (obviously SSDI doesn't think so...)
    But will keep in mind ...
    Caitlin

    Comment

    Working...
    X